炎症体
表型
程序性细胞死亡
基因
细胞生物学
生物
癌症研究
医学
遗传学
细胞凋亡
受体
作者
Ashley A. Basiorka,Kathy L. McGraw,Erika Adriana Eksioglu,Xianghong Chen,Joseph Johnson,Ling Zhang,Qing Zhang,Brittany A. Irvine,Thomas Cluzeau,David Andrew Sallman,Eric Padron,Rami S. Komrokji,Lubomir Sokol,Rebecca C. Coll,Avril A. B. Robertson,Matthew A. Cooper,John L. Cleveland,Luke A.J. O'Neill,Sheng Wei,Alan F. List
出处
期刊:Blood
[Elsevier BV]
日期:2016-10-14
卷期号:128 (25): 2960-2975
被引量:377
标识
DOI:10.1182/blood-2016-07-730556
摘要
Despite genetic heterogeneity, myelodysplastic syndromes (MDSs) share features of cytological dysplasia and ineffective hematopoiesis. We report that a hallmark of MDSs is activation of the NLRP3 inflammasome, which drives clonal expansion and pyroptotic cell death. Independent of genotype, MDS hematopoietic stem and progenitor cells (HSPCs) overexpress inflammasome proteins and manifest activated NLRP3 complexes that direct activation of caspase-1, generation of interleukin-1β (IL-1β) and IL-18, and pyroptotic cell death. Mechanistically, pyroptosis is triggered by the alarmin S100A9 that is found in excess in MDS HSPCs and bone marrow plasma. Further, like somatic gene mutations, S100A9-induced signaling activates NADPH oxidase (NOX), increasing levels of reactive oxygen species (ROS) that initiate cation influx, cell swelling, and β-catenin activation. Notably, knockdown of NLRP3 or caspase-1, neutralization of S100A9, and pharmacologic inhibition of NLRP3 or NOX suppress pyroptosis, ROS generation, and nuclear β-catenin in MDSs and are sufficient to restore effective hematopoiesis. Thus, alarmins and founder gene mutations in MDSs license a common redox-sensitive inflammasome circuit, which suggests new avenues for therapeutic intervention.
科研通智能强力驱动
Strongly Powered by AbleSci AI